Introduction: The long-term efficacy and safety of dupilumab, a fully human anti-interleukin-4-receptor-alpha monoclonal antibody, plus concomitant topical corticosteroids (TCS) were evaluated in patients with moderate-to-severe atopic dermatitis (AD).
Methods: CHRONOS (ClinicalTrials.gov: NCT02260986) was a 1-year, double-blind, randomised, placebo-controlled, parallel-group, phase 3 study in adults with moderate-to-severe AD and an inadequate response to TCS. Patients were randomised 3:1:3 to dupilumab 300 mg every week (qw), 300 mg every 2 weeks (q2w), or placebo. Patients received a standardised regimen of concomitant low-/medium-potency TCS that could be tapered or stopped as necessary or topical calcineurin inhibitors in areas inadvisable for TCS.
Results: Efficacy data were available for 740 (Week 16) Conclusions: Long-term treatment with dupilumab and concomitant topical medications significantly improved AD signs and symptoms, including pruritus, and showed an acceptable safety profile. Background: The rapid rise of atopic diseases in recent decades has increasingly turned attention to potential environmental variables that modulate allergic phenotype expression. Recent discoveries regarding the human microbiome's complex signaling with our immune system are driving research to comprehend how altered infant microflora may result in persistently impaired immunomodulation.
This systematic review and meta-analysis of published data between 2005 and 2016 seeks to clarify the evidence for a relationship between infant microbiota diversity and the development of atopic disease in later childhood.
Method: Studies were selected that analyzed the nature of the infant intestinal microbiota and the relationship to childhood atopy. Focus was directed towards studies assessing microbiota diversity although this was frequently not the primary focus of the individual papers. Selection of studies required diversity analysis calculated by non-culture methods. Exclusion of studies occurred if the assessment of children's microflora occurred after 12 months of age, where a clinical intervention was uncontrolled or if there was a lack of clear diagnosis by laboratory or clinical methods. Twelve studies met the criteria for final inclusion with eleven used within the meta-analysis. Within the 11 studies, there are 24 effect sizes. There is a spectrum of infant ages and allergic disease within the studies including atopic dermatitis, asthma/wheeze, and food sensitisation.
Results: Infants in the control group had higher diversity scores than infants in the atopic group, d = 0.4217, 95%CI = 0.1874 to 0.6559, P = .0004.
Conclusion:
There is a significant trend within the data for early infancy as the most influential time for decreased microbiome diversity and an association with later atopy. Public health implications thus arising include reduction of unnecessary antimicrobial interventions, environmental modifications that improve healthy diversity exposure, and further research into appropriate microbial signaling to foster balanced immune responses in utero and early infancy.
P69 SKIN PRICK TESTING IN THE COMMUNITY: AUDIT OF REQUESTS BY INDICATION AND ALLERGENS TESTED

M Hurst and K Kwok Labtests, Auckland, New Zealand
Skin prick testing is a resource-intensive procedure and Labtests perform approximately 10 000 tests per year. As a result of our concerns about whether these tests were being ordered appropriately, we implemented a new request form requiring ordering clinicians to state test indication and select allergens from two panels, food and aeroallergens. We then audited requests from a one-month period (March 2017).
943 requests were received, of which 858 were on the new request form (91%). Three patients were tested twice within the 1-month period. 337 patients were tested only for aeroallergen sensitivity, 160 for foods and 445 for both. 30 patients had all test indications and all allergens selected.
Allergic rhinitis/conjunctivitis was the most common indication for testing (437 requests), followed by food allergy (271), atopic dermatitis/eczema (249), asthma (126) and other (144); more than one indication could be selected. In just under half of instances where allergic rhinitis/conjunctivitis +/− asthma were the sole indications for testing, food allergens were also ordered (218/472). In over half of instances where food allergy was the sole indication for testing, aeroallergens were also tested (165/267).
These data show that in many cases inappropriate tests are being ordered. This has significant repercussions in terms of individual patient morbidity (e.g. unnecessary exclusion diets) as well as the time and resources involved in testing. Targeted education and additional interventions such as electronic ordering may help in improving request appropriateness and making these tests more useful for clinicians and patients. Background: Medical alert devices are commonly used to declare drug, food and venom allergy because they provide information in emergency situations in a readily available form, not dependent on access to medical records. However, there are currently no guidelines as to the indications for medical alert devices in allergy, the optimal terminology, or the requirement for medical validation. 
